Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

D. Davis, Ian; Martin, Andrew; R. Stockler, Martin; Begbie, Stephen; N., Kim; Chowdhury, Simon; Coskinas, Xanthi; Frydenberg, Mark; Hague, Wendy; G. Horvath, Lisa; M. Joshua, Anthony; Jane Lawrence, Nicola; Marx, Gavin; McCaffrey, John; McDermott, Ray; McJannett, Margaret; North, Scott; Parnis, Francis; R. Parulekar, Wendy; Pook, David; Neil Reaume, M.; Sandhu, Shahneen; Tan, Alvin; Hsiang Tan, Thean; Thomson, Alastair; Tu, Emily; Vera-Badillo, Francisco; Williams, Scott; Yip, Sonia; Y. Zhang, Alison; Zielinski, Robert; J. Sweeney, Christopher

doi:10.1056/nejmoa1903835

Public

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Published in New England Journal of Medicine • Jun 2, 2019

Authors:

Ian D. Davis

Andrew Martin

Martin R. Stockler

Abstract

BACKGROUND: Enzalutamide, an androgen-receptor inhibitor, has been associated with improved overall survival in men with castration-resistant prostate cancer. It is not known whether adding enzalutamide to testosterone suppression, with or without early docetaxel, will improve survival in men with m...

Subject

Enzalutamide

Medicine

Hazard ratio

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!